Alexandra Collingbourne Alexandra Collingbourne

Healx and Ovid Therapeutics enter strategic partnership

Ovid Therapeutics, a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological diseases, and Healx, the AI-powered, patient-inspired technology company pioneering the next generation of drug discovery, announces that Healx has secured from Ovid an exclusive option to license rights to develop and commercialize gaboxadol.

Read More
Alexandra Collingbourne Alexandra Collingbourne

Hoteliers Count the Costs of Bed Bugs

Hotels can now assess the cost of bed bugs to their bottom line with a newly launched free online tool from Spotta Smart Pest Systems

Read More
Alexandra Collingbourne Alexandra Collingbourne

Phico Therapeutics establishes Scientific Advisory Board

Phico Therapeutics Ltd (‘Phico’), a biotechnology company developing engineered phage technology as the basis of a new generation of antibiotics to overcome antibacterial resistance, today announced that it has established a Science Advisory Board (SAB) to provide strategic scientific guidance to the Company.

Read More
Alexandra Collingbourne Alexandra Collingbourne

Eagle Genomics Selected for Catalonia-Based Initiative to Support Expansion into Spanish-Speaking Markets

Eagle Genomics, the Deep Tech platform business pioneering the application of network science to biology across the Food and Nutrition, Biopharma, Beauty and Personal Care, and AgBio industries, announced that it has been selected to participate in the Fast-Track Programme to Barcelona-Catalonia Life Science Hub (‘Programme’), Catalonia Trade & Investment’s initiative for UK firms looking to expand to Spanish-speaking markets.

Read More
Alexandra Collingbourne Alexandra Collingbourne

DefiniGEN appoints Dr Chris Kirton as Chief Executive Officer

Cambridge, UK – 20th January 2022 – Life Science Newswire – DefiniGEN is pleased to announce the appointment of Dr Chris Kirton as Chief Executive Officer. Chris has more than 16 years of operational experience and joined DefiniGEN as Chief Operating Officer in June 2020.

Read More
Alexandra Collingbourne Alexandra Collingbourne

PhoreMost expands into new facility at Unity Campus, Cambridge, UK

PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets has announced it has relocated its headquarters to Unity Campus, a high-specification technology and innovation park, owned by leading regional property developers and investors, Howard Group, in south Cambridge.

Read More